The atopic dermatitis market offers opportunities in developing new and innovative therapies, with over 100 companies and 110 drugs in various stages of development. Key areas include novel biologic ...

Alphyn Biologics, Inc., a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, today ...

Nektar Therapeutics is rated Strong Buy based on promising Phase 2b maintenance data for REZPEG in atopic dermatitis. Click to read why NKTR is a Strong Buy.

Difamilast demonstrated safety, efficacy in multiple eczema trials, joins crisaborole, rof ...

Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the 13 hot stocks to buy with the highest upside potential. On February 2, Jefferies lowered its price target on Apogee Therapeutics Inc. (NASDAQ:APGE) ...

Dupilumab was safe and effective for the treatment of patients with severe AD who were aged 6 months to 5 years in a real-world study.

On average, equities are expected continue to deliver positive results in 2026, this time with greater breadth across sectors ...

Latest STRATA customer strengthens academic leadership in XTRAC excimer laser treatment for psoriasis, vitiligo, and atopic dermatitis ...

With their blockbuster obesity drugs, Eli Lilly and Novo Nordisk have uncovered a variety of ailments the incretin treatments can combat. | Six weeks after Eli Lilly revealed the success of phase 3b ...

The JAK inhibitors market offers significant opportunities in treating autoimmune and rheumatic diseases through diverse product development by over 40 companies and 45 drugs. Key areas include ...

Kymera Therapeutics Inc. reports fourth-quarter results Thursday, with analysts looking for signs the clinical-stage biotech can sustain its momentum through what some see as a catalyst-light year ...

We’ve tried all the creams, potions and elixirs that promise healthier, more glowing skin. But at the same time, we also know that skin health is more than, well, skin deep. That begs the question, ...